Explore
Anticancer Drugs 2021
0 Ungluers have
Faved this Work
Login to Fave
The Special Issue "Anticancer Drugs 2021" of Pharmaceuticals is focused on recent significant advances in the design, synthesis, molecular mechanism of action and therapeutic applications of anticancer drugs. This collection of preclinical research papers and reviews includes designed chemotherapeutic agents, targeted therapies and biological agents. The rationalization for the biological activity of these drugs is presented, which helps to guide the design of more effective agents. Structure–activity relationships, together with the biological context in which targets are selected for oncology drug development, are also considered.
This book is included in DOAB.
Why read this book? Have your say.
You must be logged in to comment.
Rights Information
Are you the author or publisher of this work? If so, you can claim it as yours by registering as an Unglue.it rights holder.Downloads
This work has been downloaded 66 times via unglue.it ebook links.
- 66 - pdf (CC BY) at Unglue.it.
Keywords
- 1,2,3-triazole
- 1,3,4-oxadiazole
- 3,4′-bis-guanidino
- 3-amino-4′-guanidino
- 5-fluoruracil
- 7-deaza-4′-thioadenosine derivatives
- acetamide
- adamantane
- ADC (antibody-drug conjugate)
- Age
- alkylated
- anticancer
- anticancer activity
- anticancer agents
- Apoptosis
- apoptosis induction
- aromatase inhibitor
- Bcl-2 inhibitors
- benzenesulfonamides
- benzimidazole
- BRAF
- Breast cancer
- Cancer
- cancer cell viability
- cancer vaccine
- CAR (chimeric antigen receptor)
- cardiotoxicity
- carvedilol
- cell cycle analysis
- chalcone
- chalcones
- Chemistry
- colony formation
- Combretastatin A-4
- concentration-guided dosing
- covalent binding
- CovDock
- cumulative dose
- cyclophosphamide
- cytotoxic activity
- cytotoxic agents
- Cytotoxicity
- designed multiple ligand
- diphenyl ether
- DNA fragmentation
- docking
- doxazosin
- drug efflux
- dual inhibitors
- dual-targeting molecule
- EGFR
- ELISA
- enantioselective synthesis
- entrectinib
- exportin-1
- gastric adenocarcinoma
- generic product
- H1299
- HDAC inhibitors
- HER2
- heterocyclic compound
- histopathology
- HL-60
- HT-29 cells
- hybrid compounds
- hybrid molecule
- hydrazide derivatives
- imidazoles
- imiquimod
- Immunotherapy
- in vitro
- in vivo
- indazole
- Indole-based analogues
- Inflammation
- interleukin-6
- intramolecular hydrogen bond
- Isolation
- Kidney
- larotrectinib
- letrozole
- Mathematics & science
- MD simulations
- MDA-MB-231 cells
- mechanism prediction
- miR-21
- mitoxantrone
- model informed dosing
- MTT cytotoxic assay
- MUC1
- MUC16
- mucin
- multi-kinase inhibitor
- multidrug resistance
- n/a
- NaMSA
- nitrogen scaffolds
- NTRK
- nucleoside
- Oxidative Stress
- patent review
- pemetrexed
- phenstatin
- phenyl pyridyl ether
- physiologically based pharmacokinetics
- protein kinase inhibitors
- Reference, information & interdisciplinary subjects
- Research & information: general
- resin acid
- solid/lipid nanoparticles
- sorafenib
- STAT inhibitors
- Synthesis
- TDP1
- testis
- thiourea
- thymidylate synthase
- tissue-agnostic
- toll-like receptor
- Toxicity
- Trk
- Trk fusion
- trypan blue assay
- tryptophanol
- tubulin polymerisation inhibitor
- tumor spheroids
- tyrosil-DNA-phosphodiesterase 1
- urinary bladder
- USFDA
- xanthone
Links
DOI: 10.3390/books978-3-0365-4347-5Editions